Core Viewpoint - The gene sequencing sector has shown a modest increase of 0.44%, ranking fifth among concept sectors, with notable performances from stocks like Nanjing Xinbai and Zhaoyan New Drug [1][2]. Market Performance - The gene sequencing concept saw 29 stocks rise, with Nanjing Xinbai hitting the daily limit up, and other top gainers including Heyuan Biological and Qianyuan Pharmaceutical, which rose by 8.61%, 6.96%, and 6.43% respectively [1]. - Conversely, stocks like Puni Testing, Zhongyuan Co., and Betta Pharmaceuticals experienced declines of 3.73%, 2.71%, and 2.46% respectively [1]. Capital Flow - The gene sequencing sector attracted a net inflow of 122 million yuan, with 34 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow [2]. - Zhaoyan New Drug led the sector with a net inflow of 203 million yuan, followed by Nanjing Xinbai and Qianyuan Pharmaceutical with net inflows of 111 million yuan and 64.63 million yuan respectively [2]. Capital Inflow Ratios - Nanjing Xinbai, Zhaoyan New Drug, and Heyuan Biological had the highest net inflow ratios at 43.57%, 12.72%, and 10.88% respectively [3].

Group 1 - The company is named Shanxi C&Y Pharmaceutical Group Co., Ltd, established as a joint-stock company in accordance with the Company Law of the People's Republic of China [1][2] - The registered capital of the company is RMB 248,318,563, and the actual capital is also RMB 248,318,563 [2] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 19, 2011, after an initial public offering of 33.8 million shares [1][2] Group 2 - The company's business purpose is to care for life, stemming from professionalism [3] - The company is engaged in the production of pharmaceuticals and internet information services related to pharmaceuticals [3][4] Group 3 - The company has a total of 248,318,563 shares, all of which are ordinary shares [5] - The company cannot provide financial assistance for others to acquire its shares, except for employee stock ownership plans [5][6] Group 4 - The company can increase its capital through various methods, including issuing shares to unspecified objects and reducing registered capital as per legal requirements [6][10] - The company is allowed to repurchase its shares under specific circumstances, such as reducing registered capital or for employee stock ownership plans [10][11] Group 5 - Shareholders have rights to dividends and other benefits proportional to their shareholdings, and they can participate in shareholder meetings and exercise voting rights [15][35] - The company must maintain a shareholder register based on the records provided by the securities registration and settlement institution [34] Group 6 - The company must hold an annual general meeting within six months after the end of the previous fiscal year [52] - The company can hold temporary shareholder meetings under certain conditions, such as when the number of directors is insufficient or when requested by shareholders holding more than 10% of shares [53][58]

Core Viewpoint - The document outlines the governance structure and operational regulations for Shanxi Qianyuan Pharmaceutical Group Co., Ltd, focusing on the role, responsibilities, and independence of independent directors within the company [1][2][3]. Group 1: Independent Director Definition and Responsibilities - Independent directors are defined as those who do not hold any other positions within the company and have no direct or indirect interests that could affect their independent judgment [2][3]. - The company will have five independent directors, constituting at least half of the total board members, including at least one accounting professional [2][3]. - Independent directors are obligated to act in good faith and diligence towards the company and all shareholders, ensuring the protection of minority shareholders' rights [2][3][4]. Group 2: Qualifications and Independence Criteria - Candidates for independent directors must meet specific qualifications, including relevant work experience and a clean personal record [3][4]. - Independent directors must maintain independence and cannot have significant relationships with the company or its major shareholders [4][5]. - The document specifies conditions under which individuals are disqualified from serving as independent directors, including recent legal penalties or conflicts of interest [4][5][6]. Group 3: Nomination and Election Process - The board of directors or shareholders holding more than 1% of the company's shares can propose candidates for independent directors, subject to shareholder approval [6][7]. - Candidates must provide declarations confirming their qualifications and independence before being nominated [6][7]. - If a candidate does not meet the independence criteria, the stock exchange can raise objections, and the company must disclose this information [7][8]. Group 4: Duties and Authority of Independent Directors - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [9][10]. - They have the authority to independently hire external consultants for audits or investigations and can propose meetings to address significant issues [10][11]. - Independent directors must attend board meetings and can only delegate their voting rights under specific circumstances [11][12]. Group 5: Communication and Reporting - Independent directors are required to maintain communication with minority shareholders and report any issues that hinder their ability to perform their duties [15][16]. - They must submit annual reports detailing their attendance, participation in committees, and interactions with shareholders [16][17]. - The company is responsible for providing necessary resources and support to independent directors to facilitate their duties [17][18]. Group 6: Compensation and Support - The company must provide independent directors with appropriate compensation, which is subject to board approval and must be disclosed in annual reports [18][19]. - Independent directors are entitled to reimbursement for expenses incurred while performing their duties [18][19]. - The company must ensure that independent directors have equal access to information and resources as other board members [17][18].

Core Viewpoint - The company has conducted a review of the draft for the 2025 Restricted Stock Incentive Plan and has determined that it meets the necessary legal and regulatory requirements for implementation [1][2][3] Group 1: Eligibility and Compliance - The company is eligible to implement the stock incentive plan as it has not faced any negative audit opinions or internal control issues in the last accounting year [1] - The incentive plan's targets do not include individuals who have been deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) in the last 12 months [2] - The plan complies with the relevant laws and regulations, ensuring that the interests of the company and all shareholders are not harmed [2] Group 2: Plan Approval - The Compensation and Assessment Committee unanimously agrees to implement the incentive plan and will submit the related proposals to the company's board of directors for review [3]

Group 1 - Company Name: Shanxi Qianyuan Pharmaceutical Group Co., Ltd. [1] - Stock Code: 300254 [1] - Independent Financial Advisor: Shanghai Rongzheng Enterprise Consulting Service (Group) Co., Ltd. [1] Group 2 - Compliance with Listing Company Requirements: No negative or unable to express opinions in the audit report for the most recent financial year [3] - No violations of laws, regulations, or company articles regarding profit distribution in the last 36 months [3] - No major legal violations leading to administrative penalties or market bans by the China Securities Regulatory Commission in the last 12 months [3] Group 3 - Stock Incentive Plan Compliance: Total number of shares involved in all effective stock incentive plans does not exceed 20% of the company's total share capital [4] - The proportion of reserved rights for incentive objects does not exceed 20% of the proposed granted rights [4] - The plan includes detailed disclosures regarding the incentive objects, including names, positions, and granted quantities [4][5] Group 4 - Performance Assessment Indicators: Indicators are objective, public, clear, and beneficial for enhancing the company's competitiveness [5] - The plan's effective period, authorization date, and lock-up arrangements are clearly defined [4][6] - The company has not provided financial assistance to incentive objects [8]

证券简称：仟源医药 证券代码：300254 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划 （草案）摘要 山西仟源医药集团股份有限公司 2025 年 7 月 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划（草案）摘要 声 明 本公司及全体董事保证本激励计划及其摘要不存在虚假记载、误导性陈述或 重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 2 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划（草案）摘要 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所创业板上市公司自律监管指南第 1 号——业务办理》和其他有关法律、 法规、规范性文件，以及《山西仟源医药集团股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第一类限制性股票）。股票 来源为山西仟源医药集团股份有限公司（以下简称"公司"或"本公司"）向激 励对象定向发行的公司 A 股普通股股票。 三、本激励计划拟向激励对象授予的限制性股票数量总计不超过 915.00 万 股， ...

山西仟源医药集团股份有限公司 2025 年限制性股票激励计划激励对象名单 限制性股票激励计划的分配情况 | 职务 | 获授的限制性股 | 占本计划授予 限制性股票总 | 占本计划草 案公告日股 | | --- | --- | --- | --- | | | 票数量（万股） | 数的比例 | 本总额的比 | | | | | 例 | | 一、首次授予部分 | | | | | 核心骨干人员（171 人） | 795 | 86.89% | 3.20% | | 二、预留授予部分 | 120 | 13.11% | 0.48% | | 合计 | 915 | 100.00% | 3.68% | 注：1、上述任何一名首次授予的激励对象通过全部在有效期内的股权激励计划获授的本公司股票均 未超过公司总股本的 1%。公司全部在有效期内的激励计划所涉及的标的股票总数累计不超过股权激励计 划提交股东会时公司股本总额的 20%。 2、以上合计数据与各明细数相加之和在尾数上如有差异是由于四舍五入所造成。 山西仟源医药集团股份有限公司 董事会 二〇二五年七月二十一日 ...

证券简称：仟源医药 证券代码：300254 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划 （草案） 2 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划（草案） 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所创业板上市公司自律监管指南第 1 号——业务办理》和其他有关法律、 法规、规范性文件，以及《山西仟源医药集团股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第一类限制性股票）。股票 来源为山西仟源医药集团股份有限公司（以下简称"公司"或"本公司"）向激 励对象定向发行的公司 A 股普通股股票。 山西仟源医药集团股份有限公司 2025 年 7 月 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划（草案） 声 明 本公司及全体董事保证本激励计划及其摘要不存在虚假记载、误导性陈述或 重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 3 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划（草案） 限制性股票的授予价 ...

山西仟源医药集团股份有限公司 2025 年限制性股票激励计划自查表 | 公司简称：仟源医药 | | | 股票代码：300254 | | --- | --- | --- | --- | | | 独立财务顾问：上海荣正企业咨询服务（集团）股份有限公司 | | | | 序号 | 事项 | 是否存在该 事项（是/否/ | 备注 | | | | 不适用） | | | | 上市公司合规性要求 | | | | 1 | 最近一个会计年度财务会计报告是否被注册会计师出具否定意 | 否 | | | | 见或者无法表示意见的审计报告 | | | | 2 | 最近一个会计年度财务报告内部控制被注册会计师出具否定意 | 否 | | | | 见或者无法表示意见的审计报告 | | | | 3 | 上市后最近 36 个月内出现过未按法律法规、公司章程、公开承 | 否 | | | | 诺进行利润分配的情形 | | | | 4 | 是否存在其他不适宜实施股权激励的情形 | 否 | | | 5 | 是否已经建立绩效考核体系和考核办法 | 是 | | | 6 | 是否为激励对象提供贷款以及其他任何形式的财务资助 | 否 | | | | 激励对象合规 ...

山西仟源医药集团股份有限公司薪酬与考核委员会 关于公司 2025 年限制性股票激励计划（草案）的核查意见 山西仟源医药集团股份有限公司（以下简称"公司"）薪酬与考核委员会依 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办 法》"）等相关法律、法规、规章及规范性文件和《公司章程》的有关规定，对 公司《2025 年限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"） 进行了核查，发表核查意见如下： 1、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划的 情形，包括：（1）最近一个会计年度财务会计报告被注册会计师出具否定意见 或者无法表示意见的审计报告；（2）最近一个会计年度财务报告内部控制被注 册会计师出具否定意见或无法表示意见的审计报告；（3）上市后最近 36 个月内 出现过未按法律法规、公司章程、公开承诺进行利润分配的情形；（4）法律法 规规定不得实行股权激励的；（5）中国证监会认定的其他情形。公司具备实施 股权激励计划的主体资格。 2、山西仟源医药集团股份有限公司 2025 年限 ...